About Gilead Sciences. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that various closing conditions for the transaction may not be satisfied or waived; the risk that Gilead may not realize the potential benefits of this transaction; ▇▇▇▇▇▇’s ability to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials, including those involving Trodelvy; uncertainties relating to regulatory applications for Trodelvy and related filing and approval timelines, including for the treatment of metastatic TNBC, mUC, HR+/HER2- breast cancer, NSCLC, SCLC, head and neck cancer, and endometrial cancer, in the currently anticipated timelines or at all; Gilead’s ability to receive regulatory approvals for such indications in a timely manner or at all, including regulatory approvals in Hong Kong, South Korea and Taiwan for metastatic TNBC, and the risk that any such approvals may be subject to significant limitations on use; the possibility that Gilead may make a strategic decision to discontinue development of Trodelvy for such indications and as a result, Trodelvy may never be commercialized for these indications; the risk that physicians may not see the benefits of prescribing Trodelvy; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.
Appears in 1 contract
About Gilead Sciences. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis hepatitis, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. This press Various statements in this release includes concerning ▇▇▇▇▇▇’s future expectations, plans and prospects, including without limitation, Jounce’s expectations regarding its ability to extend its cash runway may constitute forward-looking statements within for the meaning purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 that and other federal securities laws and are subject to substantial risks, uncertainties uncertainties, and other assumptions. You should not place reliance on these forward-looking statements. Although ▇▇▇▇▇▇ believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward- looking statements as a result of various important factors, including including, without limitation, Jounce’s ability to manage operating expenses and capital expenditures; Jounce’s ability to successfully demonstrate the possibility that various closing conditions for the transaction may not be satisfied or waived; the risk that Gilead may not realize the potential benefits efficacy and safety of this transactionits product candidates and future product candidates; ▇▇▇▇▇▇’s ability to initiateobtain, progress or complete clinical trials within currently anticipated timelines or at all, maintain and the possibility of unfavorable results from ongoing or additional clinical trials, including protect its intellectual property; and those involving Trodelvy; uncertainties relating to regulatory applications for Trodelvy and related filing and approval timelines, including for the treatment of metastatic TNBC, mUC, HR+/HER2- breast cancer, NSCLC, SCLC, head and neck cancer, and endometrial cancer, risks more fully discussed in the currently anticipated timelines or at all; Gileadsection entitled “Risk Factors” in Jounce’s ability to receive regulatory approvals for such indications in a timely manner or at all, including regulatory approvals in Hong Kong, South Korea and Taiwan for metastatic TNBC, and the risk that any such approvals may be subject to significant limitations on use; the possibility that Gilead may make a strategic decision to discontinue development of Trodelvy for such indications and as a result, Trodelvy may never be commercialized for these indications; the risk that physicians may not see the benefits of prescribing Trodelvy; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead’s Quarterly most recent Annual Report on Form 10-Q for the quarter ended June 30, 2022, as K filed with the U.S. Securities and Exchange Commission as well as discussions of potential risks, uncertainties, and other important factors in Jounce’s subsequent filings with the Securities and Exchange Commission. These risksAll such statements speak only as of the date made, uncertainties and other factors could cause actual results Jounce undertakes no obligation to differ materially from those referred to in the update or revise publicly any forward-looking statements. All statements other than statements , whether as a result of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of new information, future performance and involve risks and uncertainties, and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statementsevents or otherwise.
Appears in 1 contract
Sources: License Agreement